Pharmacy Website
    Clinic Website

    Intelligence » Dementia » Last Week

    Subscribe to get latest posts via email or subscribe to a RSS feed.

    Alector announces initiation of Phase 1 trial of AL001 for treating frontotemporal dementia

    Wednesday, September 19, 2018 -- Alector, a privately held biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the initiation of its Phase 1 trial called INFRONT, which is evaluating AL001, the company's product candidate for the treatment of a genetically-defined sub-population of patients with frontotemporal dementia.

    Allergan, Sosei suspend clinical development of dementia drug

    Tuesday, September 18, 2018 -- Allergan and Sosei are voluntarily suspending clinical development activities with HTL0018318 pending investigation of an unexpected toxicology finding in an animal study involving non-human primates.

    Poor Glycemic Control Associated With Higher Risk for Dementia in Older Adults With T1D

    Wednesday, September 19, 2018 -- Repeated exposure to high levels of HbA1c was associated with increased risk for dementia in a cohort of patients age ≥50 with type 1 diabetes.

    Dementia Incidence Tied to Air Pollution

    Tuesday, September 18, 2018 -- (MedPage Today) -- London study finds 40% increased risk among adults living with poorer air quality